New Drugs in Non-small Cell Lung Cancer. An Overview

Overview

Journal Lung Cancer

Specialty Oncology

Date 1995 Apr 1

PMID 7551924

Citations 2

Authors

G Giaccone

Affiliations

Soon will be listed here.

Abstract

Chemotherapy is rather ineffective in non-small cell lung cancer. However, in the last few years, a number of new anticancer agents have been developed which have definite activity in this disease. Among them are the taxanes and CPT-11, drugs with novel mechanisms of action, new antimetabolites (edatrexate and gemcitabine), and a new vinca alkaloid (vinorelbine). Furthermore, in the near future, the better understanding of lung cancer biology will help in devising new treatment strategies.

Citing Articles

Expression of the Human Serotonin 5-HT Receptor Rescues Phenotype Profile and Restores Dysregulated Biomarkers in a Glioma Model.

Courant F, Maravat M, Chen W, Gosset D, Blot L, Hervouet-Coste N Cells. 2022; 11(8).

PMID: 35455961 PMC: 9028361. DOI: 10.3390/cells11081281.

Potential activity of paclitaxel, vinorelbine and gemcitabine in anaplastic thyroid carcinoma.

Voigt W, Kegel T, Weiss M, Mueller T, Simon H, Schmoll H J Cancer Res Clin Oncol. 2005; 131(9):585-90.

PMID: 16021466 DOI: 10.1007/s00432-005-0673-0.